Single amino acid arginine starvation efficiently sensitizes cancer cells to canavanine treatment and irradiation
Open Access
- 6 June 2011
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 130 (9) , 2164-2175
Abstract
Single amino acid arginine deprivation is a promising strategy in modern metabolic anticancer therapy. Its potency to inhibit tumor growth warrants the search for rational chemo‐ and radio‐therapeutic approaches to be co‐applied. In this report, we evaluated, for the first time, the efficacy of arginine deprivation as anticancer therapy in three‐dimensional (3D) cultures of human tumor cells, and propose a new combinatorial metabolic‐chemo‐radio‐treatment regime based on arginine starvation, low doses of arginine natural analog canavanine and irradiation. A sophisticated experimental setup was designed to evaluate the impact of arginine starvation on four human epithelial cancer cell lines in 2D monolayer and 3D spheroid culture. Radioresponse was assessed in colony formation assays and by monitoring spheroid regrowth probability following single dose irradiation using a standardized spheroid‐based test platform. Surviving fraction at 2 Gy (SF2Gy) and spheroid control dose50(SCD50) were calculated as analytical endpoints. Cancer cells in spheroids are much more resistant to arginine starvation than in 2D culture. Spheroid volume stagnated during arginine deprivation, but even after 10 days of starvation, 100% of the spheroids regrew. Combination treatment, however, was remarkably efficient. In particular, pretreatment of cancer cells with the arginine‐degrading enzyme arginase combined with or without low concentration of canavanine substantially enhanced cell radioresponse reflected by a loss in spheroid regrowth probability and SCD50values reduced by a factor of 1.5–3. Our data strongly suggest that arginine withdrawal alone or in combination with canavanine is a promising antitumor strategy with potential to enhance cancer cure by irradiation.Keywords
This publication has 41 references indexed in Scilit:
- Canavanine augments proapoptotic effects of arginine deprivation in cultured human cancer cellsAnti-Cancer Drugs, 2011
- A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patientsBritish Journal of Cancer, 2010
- Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancerInternational Journal of Cancer, 2010
- Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/HIF-1α/Sp4Molecular Cancer Therapeutics, 2009
- Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum‐induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancerInternational Journal of Cancer, 2009
- Assessment of Apoptosis by Immunohistochemistry to Active Caspase-3, Active Caspase-7, or Cleaved PARP in Monolayer Cells and Spheroid and Subcutaneous Xenografts of Human CarcinomaJournal of Histochemistry & Cytochemistry, 2008
- Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminaseInternational Journal of Cancer, 2008
- Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivationviaarginine deiminaseInternational Journal of Cancer, 2006
- Incidence and distribution of argininosuccinate synthetase deficiency in human cancersCancer, 2004
- Growth Inhibition of A549 Human Lung Adenocarcinoma Cells by L‐Canavanine Is Associated with p21/WAF1 InductionJapanese Journal of Cancer Research, 1999